Drug intelligence / Profile preview

MSB-3

Development stage: Preclinical
Lead developer: ASAKE Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

MSB-3 is a small molecule therapeutic candidate currently in preclinical development by ASAKE Biotechnology for the treatment of Type 1 Diabetes (T1D). The compound is designed to intervene in the disease process by modulating pathways within pancreatic beta cells that govern insulin production and programmed cell death (apoptosis). By protecting beta cells from destruction and enhancing their secretory capacity, MSB-3 represents a potential disease-modifying approach to maintaining glycemic control in T1D patients.

Beyond the preview

Go deeper on MSB-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSB-3.

Explore the full profile